【佳學(xué)基因檢測(cè)】監(jiān)測(cè)未經(jīng)治療的非小細(xì)胞肺癌患者的循環(huán)腫瘤 DNA

基因檢測(cè)要多少錢—答案

在高峰論壇中了解《Int J Mol Sci》在.?2022 Aug 23;23(17):9527.發(fā)表了一篇題目為《監(jiān)測(cè)未經(jīng)治療的非小細(xì)胞肺癌患者的循環(huán)腫瘤 DNA》腫瘤靶向藥物治療基因檢測(cè)臨床研究文章。該研究由Woo Kyung Ryu,?Sekyung Oh,?Jun Hyeok Lim,?Seung Jae Lee,?Hyun-Tae Shin,?Jeong-Seon Ryu?等完成。促進(jìn)了腫瘤的正確治療與個(gè)性化用藥的發(fā)展，進(jìn)一步強(qiáng)調(diào)了基因信息檢測(cè)與分析的重要性。

腫瘤靶向藥物及正確治療臨床研究?jī)?nèi)容關(guān)鍵詞：

循環(huán)腫瘤DNA,監(jiān)測(cè),非小細(xì)胞肺癌

腫瘤靶向治療基因檢測(cè)臨床應(yīng)用結(jié)果

循環(huán)腫瘤 DNA (ctDNA) 已被用于監(jiān)測(cè)接受靶向藥物突變治療的非小細(xì)胞肺癌 (NSCLC) 患者的臨床過(guò)程。然而，盡管提供了關(guān)于 NSCLC 如何自然進(jìn)展的寶貴信息，但 ctDNA 用于臨床過(guò)程監(jiān)測(cè)和預(yù)測(cè)沒有可藥物突變的初治 NSCLC 患者的臨床效用仍然未知。我們通過(guò)收集臨床信息、放射學(xué)數(shù)據(jù)和血漿樣本，縱向跟蹤了總共 12 名未接受過(guò)治療的 NSCLC 患者，這些患者沒有攜帶 EGFR 和 ALK 突變。相互比較了 ctDNA 水平和腫瘤負(fù)荷 (TB) 的變化。就診斷時(shí)的 ctDNA 檢測(cè)分析了新的轉(zhuǎn)移發(fā)展、體積倍增時(shí)間 (VDT) 和總生存期 (總生存期)。在 7 名 (58.3%) 患者的血漿中檢測(cè)到 ctDNA。在相當(dāng)大一部分（57.1%）患者中，ctDNA 水平的變化與結(jié)核病相關(guān)，并且還與其他患者的腦轉(zhuǎn)移、腫瘤壞死或肺炎有關(guān)。所有進(jìn)行 ctDNA 檢測(cè)的患者在隨訪期間在診斷時(shí)沒有轉(zhuǎn)移的器官中都出現(xiàn)了新的轉(zhuǎn)移。未檢測(cè)到 ctDNA 的患者未發(fā)生新的轉(zhuǎn)移（中位隨訪時(shí)間：9.8 個(gè)月）。此外，與未檢測(cè)到 ctDNA 的患者相比，檢測(cè)到 ctDNA 的患者 VDT 更短（p = 0.039），總生存期 更差（p = 0.019）?？梢酝ㄟ^(guò)測(cè)量 ctDNA 水平來(lái)監(jiān)測(cè) NSCLC 進(jìn)展的自然過(guò)程。診斷時(shí)檢測(cè)ctDNA可以預(yù)測(cè)NSCLC患者新轉(zhuǎn)移的發(fā)展、腫瘤快速生長(zhǎng)和生存率低。監(jiān)測(cè)；非小細(xì)胞肺癌。

腫瘤發(fā)生與反復(fù)轉(zhuǎn)移國(guó)際數(shù)據(jù)庫(kù)描述：

Circulating tumor DNA (ctDNA) has been utilized to monitor the clinical course of patients of non-small-cell lung cancer (NSCLC) who receive therapies targeting druggable mutations. However, despite providing valuable information on how NSCLC would naturally progress, the clinical utility of ctDNA for clinical-course monitoring and prediction of treatment-na?ve NSCLC patients without druggable mutations remain unknown. We longitudinally followed a total of 12 treatment-na?ve NSCLC patients, who did not harbor?EGFR?and?ALK?mutations, by collecting clinical information, radiological data, and plasma samples. Changes in ctDNA levels and tumor burden (TB) were compared with each other. New metastasis development, volume doubling time (VDT), and overall survival (OS) were analyzed regarding ctDNA detection at diagnosis. ctDNA was detected in the plasma of seven (58.3%) patients. Changes in ctDNA levels correlated with those in TB in a substantial fraction (57.1%) of patients and was also associated with brain metastasis, tumor necrosis, or pneumonia in other patients. All patients with ctDNA detection developed new metastasis during follow-ups in the organs that had been devoid of metastasis at diagnosis. The patients without ctDNA detection did not develop new metastasis (median duration of follow-ups: 9.8 months). In addition, patients with ctDNA detection had shorter VDT (p?= 0.039) and worse OS (p?= 0.019) than those without ctDNA detection. The natural course of NSCLC progression can be monitored by measuring ctDNA levels. Detection of ctDNA at diagnosis can predict development of new metastasis, rapid tumor growth and poor survival of NSCLC patients.Keywords:?circulating tumor DNA; monitoring; non-small-cell lung cancer.